Increased Chondrogenic Potential of Mesenchymal Cells From Adipose Tissue Versus Bone Marrow‐Derived Cells in Osteoarthritic In Vitro Models

Abstract

Primarily, to compare the behavior of human mesenchymal stem cells (MSCs) derived from bone marrow (hBMSCs) and adipose tissue (hADSCs) in an osteoarthritic (OA) microenvironment; secondly, to investigate the reaction of these cell types in two alternative in vitro culture systems, obtained by using TNFα and/or IL1β as inflammation mediators, or by using synovial fluid harvested by OA patients (OSF) to simulate the complex inflamed knee microenvironment. 3D micromass cultures of hBMSCs or hADSCs were grown in chondrogenic medium (CTR), in the presence of TNFα and/or IL1β, or synovial fluid from OA patients. After 1 month of culture, the chondrogenic differentiation of micromasses was evaluated by gene expression, matrix composition, and organization. Both hMSCs types formed mature micromasses in CTR, but a better response of hADSCs to the inflammatory environment was documented by micromass area and Bern score evaluations. The addition of OSF elicited a milder reaction than with TNFα and/or IL1β by both cell types, probably due to the presence of both catabolic and protective factors. In particular, SOX9 and ACAN gene expression and GAG synthesis were more abundant in hADSCs than hBMSCs when cultured in OSF. The expression of MMP1 was increased for both hMSCs in inflammatory conditions, but in particular by hBMSCs. hADSCs showed an increased chondrogenic potential in inflammatory culture systems, suggesting a better response of hADSCs in the OA environment, thus underlining the importance of appropriate in vitro models to study MSCs and potential advantages of using these cells for future clinical applications. J. Cell. Physiol. 232: 1478-1488, 2017. © 2016 Wiley Periodicals, Inc.

Differential Effector Response of Amnion‐ and Adipose‐Derived Mesenchymal Stem Cells to Inflammation; Implications for Intradiscal Therapy

“…In the present study, although chondrogenesis appeared to be hampered by inflammation in both MSC types compared with their respective non‐inflammatory controls, AM‐MSC cultures yielded larger, intact chondrogenic pellets, enhanced histological staining, and quantification of GAG compared with AD‐MSCs. Similar differences were observed by others when comparing the effects of IL‐1β (10 ng/ml), TNF‐α (50 ng/ml), or human osteoarthritic synovial fluid on AD‐ and BM‐MSC chondrogenesis . In the previous studies, it was found that although AD‐MSCs pellets demonstrated histological irregularities including; voids in the pellet, altered cell nucleus morphology, smaller pellet size, and reduced GAG staining compared with non‐inflammatory controls, they appeared to fare better than BM‐MSCs cultures .…”

Bone marrow aspirate clot: A technical complication or a smart approach for musculoskeletal tissue regeneration?

“…In our laboratory, we routinely sample BMA from different sources (BM, adipose tissue, synovial fluid, blood … etc) from both humans and animals (Della Bella et al, ; Pagani et al, ; Veronesi, Pagani, Della Bella, Giavaresi, & Fini, , Veronesi et al, ). Recently, we started to sample and evaluate BMA from the vertebral bodies of patients undergoing spine surgery (unpublished).…”

Preliminary Clinical Results With Lipoaspirate Stromal Vascular Cell Fraction in Treatment of Patients With Knee Osteoarthritis

“…19, 6 2017 им характеристикам соответствовала общепри-нятым критериям: высокая жизнеспособность наряду с высоким содержанием предшествен-ников МСК и вариабельной экспрессией CD34 (данные не представлены). Следует отметить, что именно в лечении па-циентов с дегенеративными заболеваниями су-ставов терапевтическая «ценность» клеток жи-ровой ткани выше по сравнению, например, с костным мозгом, поскольку МСК жировой тка-ни отличаются от костномозговых МСК более высоким хондрогенным потенциалом [24]. При этом безопасность и хорошая переносимость продемонстрированы для разных путей введе-ния, включая системный [26,28] и локальный (внутрисуставной) [7,12].…”

“…При этом безопасность и хорошая переносимость продемонстрированы для разных путей введе-ния, включая системный [26,28] и локальный (внутрисуставной) [7,12]. Тем не менее у паци-ентов с ДОА внутрисуставное введение является предпочтительным -не только в силу «адресной» доставки клеток, но и вследствие способности синовиальной жидкости пациентов при контакте с МСК усиливать хондрогенный потенциал по-следних [24].…”